

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

Scythian Biosciences Corp. Begins Trading on the TSXV under Symbol “SCYB”

Toronto, ON – August 8, 2017 – Further to its press release dated August 2, 2017, Scythian Biosciences Corp. (the “**Company**” or “**Scythian**”, formerly Kitrinor Metals Inc., (TSXV: SCYB) is pleased to announce that the Company has received approval from the Toronto Venture Exchange Inc. (the “**TSXV**”) to list its common shares on the TSXV as a research and development in the physical, engineering and life sciences company. The common shares of the Company commenced trading on the TSXV at the opening of market today, Tuesday, August 8, 2017, under the trading symbol “SCYB”.

Scythian's CEO and Chairman commented, “We are pleased to have completed this major milestone. The TSXV listing represents greater accessibility and liquidity to a broader group of investors and increased market recognition. We will continue to work with the University of Miami's research team to develop a drug regime that can treat concussions and traumatic brain injury.”

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Contact Information

For further information, please contact:

Scythian Biosciences Corp.
Jonathan Gilbert
CEO
Phone: (212) 729-9208

Email: info@scythianbio.com

Cautionary Statements

*This press release may contain certain forward-looking information and statements (“**forward-looking information**”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including the risk factors discussed in the Filing Statement which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.*